Substance P-Related Neuro-Immune-Epithelial Interactions in GORD
Overview
This study investigates the role of Substance P (SP) in gastro-oesophageal reflux disease (GORD), highlighting its receptor expression and inflammatory effects on the oesophageal mucosa. Findings suggest that SP may contribute to mucosal damage through neuro-immune interactions.
Background
Gastro-oesophageal reflux disease (GORD) affects a significant portion of the population and is characterized by symptoms such as heartburn, which result from the activation of sensory nerve fibers in the oesophageal mucosa. Understanding the neuro-immune-epithelial interactions in GORD is crucial for developing targeted therapies, particularly as inflammatory markers are upregulated in affected patients.
Data Highlights
Group
N
NK1R Expression
MRGPRX2+ Mast Cells
Healthy Controls
10
Low
Low
Functional Heartburn
10
Moderate
Moderate
Non-Erosive Reflux Disease
14
High
High
Erosive Reflux Disease
13
Higher
Higher
Key Findings
NK1R expression is significantly higher in NERD and ERD compared to healthy controls.
SP exposure in NE-1 cells induces NF-κB phosphorylation and cytokine release (IL-6 and IL-8).
The density of MRGPRX2+ mast cells is significantly increased in NERD and ERD mucosa.
32% of SP+ nerve fibers are located within 10 µm of a mast cell, indicating close neuro-immune interactions.
SP may play a role in the pathogenesis of mucosal damage in GORD through inflammatory pathways.
Clinical Implications
The findings suggest that targeting SP receptors, particularly NK1R and MRGPRX2, may offer new therapeutic avenues for managing GORD. Understanding the inflammatory pathways activated by SP could lead to more effective treatments for patients with NERD and ERD.
Conclusion
Substance P and its receptors are implicated in the inflammatory processes of GORD, highlighting the importance of neuro-immune interactions in the disease's pathophysiology. Further research may elucidate potential therapeutic targets.
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.